Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 33Lymphoid 10Other hematologic neoplasm 9Thoracic 2Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Other neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Dermatologic 1Classical hematology 1

Conditions

Ovarian Neoplasms 359Endometrial Neoplasms 207Uterine Cervical Neoplasms 187Breast Neoplasms 109Fallopian Tube Neoplasms 96Colorectal Neoplasms 83Carcinoma, Non-Small-Cell Lung 76Neoplasms 65Pancreatic Neoplasms 59Stomach Neoplasms 55Neoplasm Metastasis 51Prostatic Neoplasms 50Lung Neoplasms 46Melanoma 43Carcinoma, Ovarian Epithelial 41Triple Negative Breast Neoplasms 38Squamous Cell Carcinoma of Head and Neck 36Esophageal Neoplasms 35Carcinoma, Renal Cell 35Colonic Neoplasms 31Urinary Bladder Neoplasms 30Peritoneal Neoplasms 29Head and Neck Neoplasms 28Vulvar Neoplasms 26Uterine Neoplasms 26Carcinoma, Hepatocellular 26Carcinoma, Transitional Cell 24Small Cell Lung Carcinoma 23Sarcoma 20Rectal Neoplasms 19

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × Gynecologic × 90 days × Clear all
NCT04354246 2026-05-12

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Compugen Ltd

Phase 1 Completed
94 enrolled
GastrointestinalGynecologicHead & NeckPlasma cellThoracic

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Lung Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡